A novel mechanism of neuroprotection: Blood glutamate grabber

Journal of Cerebral Blood Flow and Metabolism

Volumn 36, Issue 2, 2016, Pages 292-301

  Castillo, José ^a   Loza, María Isabel ^a,b   Mirelman, David ^c   Brea, José ^a,b   Blanco, Miguel ^a   Sobrino, Tomás ^a   Campos, Francisco ^a  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b Universidade de Santiago de Compostela and Instituto de Investigación Sanitaria de Santiago de Compostela   (Spain)

^c WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Blood brain barrier; brain ischemia; experimental; glutamate; neuroprotection

Indexed keywords

GLUTAMATE RECEPTOR ANTAGONIST; GLUTAMIC ACID; PYRUVIC ACID; AMINO ACID RECEPTOR BLOCKING AGENT; GLUTAMATE TRANSPORTER; NEUROPROTECTIVE AGENT;

BRAIN CIRCULATION; CEREBROVASCULAR ACCIDENT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; EXCITOTOXICITY; HEMODIALYSIS; HUMAN; NEUROPATHOLOGY; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PERITONEAL DIALYSIS; PRIORITY JOURNAL; REVIEW; STROKE PATIENT; ANIMAL; BLOOD BRAIN BARRIER; BRAIN ISCHEMIA; DRUG EFFECTS; METABOLISM; STROKE;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN ISCHEMIA; EXCITATORY AMINO ACID ANTAGONISTS; GLUTAMATE PLASMA MEMBRANE TRANSPORT PROTEINS; GLUTAMIC ACID; HUMANS; NEUROPROTECTION; NEUROPROTECTIVE AGENTS; STROKE;

EID: 84961367856     PISSN: 0271678X     EISSN: 15597016     Source Type: Journal    
DOI: 10.1177/0271678X15606721     Document Type: Review

References (64)

1. Howard G and Goff DC. Population shifts and the future of stroke: forecast of the future burden of stroke. Ann N Y Acad Sci 2012; 1268: 14-20.
2. Feigin VL, Forouzanfar MH, Krishnamurthi R, et al. on behalf of the Global Burden of Diseases, Injuries, Risk Factors Study 209109 (GBD 2010) and the GBD Stroke Experts Group. Global and regional burden of stroke during 1990-2010: findings from the Global Burden of Disease Study 2010. Lancet 2014; 383: 245-254.
3. Appireddy RM, Demchuk AM, Goyal M, et al. Endovascular therapy for ischemic stroke. J Clin Neurol 2015; 11: 1-8.
4. Heiss WD and Rosner G. Functional recovery of cortical neurons as related to degree and duration of ischemia. Ann Neurol 1983; 14: 294-301.
5. Mortimer AM, Bradley MD and Renowden SA. Endovascular therapy in hyperacute ischaemic stroke: history and current status. Interv Neuroradiol 2013; 19: 506-518.
6. Rha J-H and Saver JL. The impact of recanalization on ischemic stroke outcome: a meta-Analysis. Stroke 2007; 38: 967-973.
7. Asadi H, Yan B, Dowling R, et al. Advances in medical revascularisation treatment in acute ischemic stroke. Thrombosis 2014; 714218.
8. Tsivgoulis G, Katsanos AH and Alexandrov AV. Reperfusion therapies of acute ischemic stroke: potentials and failures. Front Neurol 2014; 5: 215.
9. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333: 1581-1587.
10. Hacke W, Kaste M, Bluhmki E, et al. ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008; 359: 1317-1329.
11. Lansberg MG, Bluhmki E and Thijs VN. Efficacy and safety of tissue plasminogen activator 3 to 4.5 hours after acute ischemic stroke: a metaanalysis. Stroke 2009; 40: 2438-2441.
12. Hacke W, Donnan G, Fieschi C, et al. ATLANTIS Trials Investigators; ECASS Trials Investigators; NINDS rt-PA Study Group Intestigators. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trial. Lancet 2004; 363: 768-774.
13. Wardlaw JM, Murray V, Berge E, et al. Recombinant tissue plasminogen activator for acute ischaemic stroke?. An update systematic review and meta-Analysis. Lancet 2012; 379: 2364-2372.
14. Toni D, Lorenzano S, Puca E, et al. The SITS-MOST registry. Neurol Sci 2006; 27(suppl 3): S260-S262.
15. Wardlaw JM, Murray V, Berge E, et al.; SITS-MOST Investigators. Thrombolysis with alteplase for acute ischaemic stroke in the safe implementation of thrombolysis in stroke-monitoring study (SITS-MOST): an observational study. Lancet 2007; 369: 275-282.
16. Gomis M and Dávalos A. Recanalization and reperfusion therapies of acute ischemic stroke: what have we learned, what are the major research questions, and where are we headed?. Front Neurol 2014; 5: 226.
17. Ip HL and Liebeskind DS. The future of ischemic stroke: flow from prehospital neuroprotection to definitive reperfusion. Intervent Neurol 2013; 2: 105-117.
18. Kleindorfer D, de los Rios F, Khatri P, et al. Temporal trends in acute stroke management. Stroke 2013; 44(suppl 1): S129-S131.
19. Suwanwela NC. Stroke epidemiology in Thailand. JOS 2014; 16: 1-7.
20. Lucas DR and Newhouse JP. The toxic effect of sodium L-glutamate on the inner layers of the retina. AMA Arch Opthalmol 1957; 58: 193-201.
21. Van Harreveld A. Compounds in brain extracts causing spreading depression of cerebral cortical activity and contraction of crustacean muscle. J Neurochem 1959; 3: 300-315.
22. Lai TW, Zhang S and Wang YT. Excitotoxicity and stroke: identifying novel targets for neuroprotection. Prog Neurobiol 2014; 115: 157-188.
23. Danbolt NC. Glutamate uptake. Prog Neurobiol 2001; 65: 1-105.
24. Hawkins RA, Mokashi A, Dejoseph MR, et al. Glutamate permeability at the blood-brain barrier in insulinopenic and insulin-resistant rats. Metabolism 2010; 59: 258-266.
25. Leibowitz A, Boyko M, Shapira Y, et al. Blood glutamate scavenging: insight into neuroprotection. Int J Mol Sci 2012; 13: 10041-10066.
26. ÓKace RL, Martínez-López I, DeJoseph MR, et al. Na+Dependent glutamate transporters (EAAT1, EAAT2, and EAAT3) of the blood-brain barrier. A mechanism for glutamate removal. J Biol Chem 1999; 274: 31891-31895.
27. Jia M, Njapo SA, Rastogi V, et al. Taming glutamate excitotoxicity: strategic pathway modulation for neuroprotection. CNS Drugs 2015; 29: 153-162.
28. Cederberg HH, Uhd NC and Brodin B. Glutamate efflux at the blood-brain barrier: cellular mechanisms and potential clinical relevance. Arch Med Res 2014; 45: 639-645.
29. Terasaki Y, Liu Y, Hayakawa K, et al. Mechanisms of neurovascular dysfunction in acute ischemic brain. Curr Med Chem 2014; 21: 2035-2042.
30. Mathur BN and Deutch AY. Rat meningeal and brain microvasculature pericytes co-Express the vesicular glutamate transporters 2 and 3. Neurosci Lett 2008; 435: 90-94.
31. Basuroy S, Leffler CW and Parfenova H. CORM-A1 prevents blood-brain barrier dysfunction caused by ionotropic glutamate receptor-mediated endothelial oxidative stress and apoptosis. Am J Physiol Cell Physiol 2013; 304: C1105-C1115.
32. Castillo MR and Babson JR. Ca2+Dependent mechanisms of cell injury in cultured cortical neurons. Neuroscience 1998; 86: 1133-1144.
33. Castillo J, Dávalos A, Naveiro J, et al. Neuroexcitatory amino acids and their relation to infarct size and neurological deficit in ischemic stroke. Stroke 1996; 27: 1060-1065.
34. Castillo J, Dávalos A and Noya M. Progression of ischaemic stroke and excitotoxic aminoacids. Lancet 1997; 349: 79-83.
35. Castillo J, Dávalos A and Noya M. Aggravation of acute ischemic stroke by hyperthermia is related to an excitotoxic mechanism. Cerebrovasc Dis 1999; 9: 22-27.
36. Castillo J, Martínez F, Corredera E, et al. Amino acid transmitters in patients with headache during the acute phase of cerebrovascular ischemic disease. Stroke 1995; 26: 2035-2039.
37. Ogden KK and Traynelis SF. New advances in NMDA receptor pharmacology. Trends Pharmacol Sci 2011; 32: 726-733.
38. Kalia LV, Kalia SK and Salter MW. NMDA receptors in clinical neurology: excitatory times ahead. Lancet Neurol 2008; 7: 742-755.
39. Grupke S, Hall J, Dobbs M, et al. Understanding history, and not repeating it. Neuroprotection for acute ischemic stroke: from review to preview. Clin Neurol Neurosurg 2015; 129: 1-9.
40. Muir KW. Glutamate-based therapeutic approaches: clinical trials with NMDA antagonist. Curr Opin Pharmacol 2006; 6: 53-60.
41. Ikonomidou C and Turski L. Why did NMDA receptor antagonist fail clinical trials for stroke and traumatic brain injury?. Lancet Neurol 2002; 1: 383-386.
42. Korczyn AD, BraininMand Guekht A. Neuroprotection in ischemic stroke: what does the future hold?. Expert Rev Neurother 2015; 15: 227-229.
43. Campos F, Sobrino T, Ramos-Cabrer P, et al. Oxalacetate: a novel neuroprotective for acute ischemic stroke. Int J Biochem Cell Biol 2012; 44: 262-265.
44. Teichberg VI, Cohen-Kashi-Malina K, Cooper I, et al. Homeostasis of glutamate in brain fluids: an accelerated brain-To-blood efflux of excess glutamate is produced by blood glutamate scavenging and offers protection from neuropathologies. Neuroscience 2009; 158: 301-308.
45. Gottlieb M, Wang Y and Teichberg VI. Blood-mediated scavenging of cerebrospinal fluid glutamate. J Neurochem 2003; 87: 119-126.
46. Nagy D, Marosi M, Kis Z, et al. Oxaloacetate decreases the infarct size and attenuates the reduction in evoked responses after photothrombotic focal ischemia in the rat cortex. Cell Mol Neurobiol 2009; 29: 827-835.
47. Campos F, Sobrino T, Ramos-Cabrer P, et al. Neuroprotection by glutamate oxaloacetate transaminase in ischemic stroke: an experimental study. J Cereb Blood Flow Metab 2011; 31: 1378-1386.
48. Philip M, Benatar M, Fisher M, et al. Methodological quality of animal studies of neuroprotective agents currently in phase II/III acute ischemic stroke trials. Stroke 2009; 40: 577-581.
49. Knapp L, Gellért L, Kocsis K, et al. Neuroprotective effect of oxaloacetate in a focal brain ischemic model in the rat. Cell Mol Neurobiol 2015; 35: 17-22.
50. Campos F, Rodríguez-Yáñez M, Castellanos M, et al. Blood levels of glutamate oxalacetate transaminase are more strongly associated with good outcome in acute ischaemic stroke than glutamate pyruvate transaminase levels. Clin Sci (Lond) 2011; 121: 11-17.
51. Campos F, Rodríguez-Yáñez M, Castellanos M, et al. High blood glutamate oxaloacetate transaminase levels are associated with good functional outcome in acute ischemic stroke. J Cereb Blood Flow Metab 2011; 31: 1387-1393.
52. Chen SY, Zhao YD, Li J, et al. Plasma levels of glutamate during stroke is associated with development of poststroke depression. Psychoneuroendocrinology 2014; 47: 126-135.
53. Meng X, Li N, Guo D-Z, et al. High plasma glutamate levels are associated with poor functional outcome in acute ischemic stroke. Cell Mol Neurobiol 2015; 35: 159-165.
54. Yoshikawa K. Studies on the anti-Diabetic effect of sodium oxaloacetate. Tohoku J Exp Med 1968; 96: 127-141.
55. Pérez-Mato M, Ramos-Cabrer P, Sobrino T, et al. Human recombinant glutamate oxaloacetate transaminase 1 (GOT1) supplemented with oxaloacetate induces a protective effect after cerebral ischemia. Cell Death Dis 2014; 5: e992.
56. Tian Z, Liu H, Su X, et al. Role of elevated liver transaminase levels in the diagnosis of liver injury after blunt abdominal trauma. Exp Ther Med 2012; 4: 255-260.
57. Zlotnik A, Gurevich B, Tkachov S, et al. Brain neuroprotection by scavenging blood glutamate. Exp Neurol 2007; 203: 213-220.
58. Boyko M, Zlotnik A, Gruenbaum BF, et al. Pyruvate?s blood glutamate scavenging activity contributes to the spectrum of its neuroprotective mechanisms in a rat model of stroke. Eur J Neurosci 2011; 34: 1432-1441.
59. Boyko M, Zlotnik A, Gruenbaum BF, et al. The effects of hemodialysis on blood glutamate levels in chronic renal failure: Implementation for neuroprotection. J Crit Care 2012; 27: 741-747.
60. Rogachev B, Tsesis S, Gruenbaum BF, et al. The effects of peritoneal dialysis on blood glutamate levels: Implementation for neuroprotection. J Neurosurg Anesthesiol 2013; 25: 262-266.
61. GodinoMdel C, Romera VG, Sánchez-Tomero JA, et al. Amelioration of ischemic brain damage by peritoneal dialysis. J Clin Invest 2013; 123: 4359-4363.
62. Fagan SC. Drug repurposing for drug development in stroke. Pharmacotherapy 2010; 30: 51S-54S.
63. Corbett A, Pickett J, Burns A, et al. Drug repositioning for Alzeimer?s disease. Nat Rev Drug Discov 2012; 11: 833-846.
64. Silva-Candal AD, Vieites-Prado A, Gutiérrez-Fernández M, et al. Blood glutamate grabbing does not reduce the hematoma in an hemorrhage model but it is a safe excitotoxic treatment modality. J Cereb Blood Flow Metab 2015; 35: 1206-1212.